Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma

Robert A. Kyle, S Vincent Rajkumar

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

In 1978, the term "monoclonal gammopathy of undetermined significance" (MGUS) was introduced. MGUS is defined as a serum monoclonal (M) protein less than 3.0 g/dL; less than 10% plasma cells in the bone marrow, if done; little or no M protein in the urine; and absence of lytic bone lesions, anemia, hypercalcemia or renal insufficiency. This article discusses the recognition, prevalence, natural history, and progression of MGUS. Management of the disease is discussed along with its association with other disorders. Information on smoldering multiple myeloma is included.

Original languageEnglish (US)
Pages (from-to)1093-1113
Number of pages21
JournalHematology/Oncology Clinics of North America
Volume21
Issue number6
DOIs
StatePublished - Dec 2007

Fingerprint

Monoclonal Gammopathy of Undetermined Significance
Multiple Myeloma
Hypercalcemia
Disease Management
Plasma Cells
Natural History
Renal Insufficiency
Anemia
Proteins
Bone Marrow
Urine
Bone and Bones
Serum

ASJC Scopus subject areas

  • Oncology
  • Hematology

Cite this

Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma. / Kyle, Robert A.; Rajkumar, S Vincent.

In: Hematology/Oncology Clinics of North America, Vol. 21, No. 6, 12.2007, p. 1093-1113.

Research output: Contribution to journalArticle

@article{b7d6f3e1e6724e0fb35907b43fc95050,
title = "Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma",
abstract = "In 1978, the term {"}monoclonal gammopathy of undetermined significance{"} (MGUS) was introduced. MGUS is defined as a serum monoclonal (M) protein less than 3.0 g/dL; less than 10{\%} plasma cells in the bone marrow, if done; little or no M protein in the urine; and absence of lytic bone lesions, anemia, hypercalcemia or renal insufficiency. This article discusses the recognition, prevalence, natural history, and progression of MGUS. Management of the disease is discussed along with its association with other disorders. Information on smoldering multiple myeloma is included.",
author = "Kyle, {Robert A.} and Rajkumar, {S Vincent}",
year = "2007",
month = "12",
doi = "10.1016/j.hoc.2007.08.005",
language = "English (US)",
volume = "21",
pages = "1093--1113",
journal = "Hematology/Oncology Clinics of North America",
issn = "0889-8588",
publisher = "W.B. Saunders Ltd",
number = "6",

}

TY - JOUR

T1 - Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma

AU - Kyle, Robert A.

AU - Rajkumar, S Vincent

PY - 2007/12

Y1 - 2007/12

N2 - In 1978, the term "monoclonal gammopathy of undetermined significance" (MGUS) was introduced. MGUS is defined as a serum monoclonal (M) protein less than 3.0 g/dL; less than 10% plasma cells in the bone marrow, if done; little or no M protein in the urine; and absence of lytic bone lesions, anemia, hypercalcemia or renal insufficiency. This article discusses the recognition, prevalence, natural history, and progression of MGUS. Management of the disease is discussed along with its association with other disorders. Information on smoldering multiple myeloma is included.

AB - In 1978, the term "monoclonal gammopathy of undetermined significance" (MGUS) was introduced. MGUS is defined as a serum monoclonal (M) protein less than 3.0 g/dL; less than 10% plasma cells in the bone marrow, if done; little or no M protein in the urine; and absence of lytic bone lesions, anemia, hypercalcemia or renal insufficiency. This article discusses the recognition, prevalence, natural history, and progression of MGUS. Management of the disease is discussed along with its association with other disorders. Information on smoldering multiple myeloma is included.

UR - http://www.scopus.com/inward/record.url?scp=35748932962&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=35748932962&partnerID=8YFLogxK

U2 - 10.1016/j.hoc.2007.08.005

DO - 10.1016/j.hoc.2007.08.005

M3 - Article

VL - 21

SP - 1093

EP - 1113

JO - Hematology/Oncology Clinics of North America

JF - Hematology/Oncology Clinics of North America

SN - 0889-8588

IS - 6

ER -